PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China · Delayed Price · Currency is CNY 45.24
-1.02 (-2.20%)
Aug 8, 2025, 2:45 PM CST
Theseus Pharmaceuticals Revenue
PharmaBlock Sciences (Nanjing) had revenue of 455.02M CNY in the quarter ending March 31, 2025, with 20.55% growth. This brings the company's revenue in the last twelve months to 1.77B, up 2.73% year-over-year. In the year 2024, PharmaBlock Sciences (Nanjing) had annual revenue of 1.69B, down -2.12%.
Revenue (ttm)
1.77B
Revenue Growth
+2.73%
P/S Ratio
5.21
Revenue / Employee
719.42K
Employees
2,455
Market Cap
9.20B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.69B | -36.58M | -2.12% |
| Dec 31, 2023 | 1.73B | 130.50M | 8.18% |
| Jan 1, 2023 | 1.59B | 393.07M | 32.71% |
| Dec 31, 2021 | 1.20B | 179.40M | 17.55% |
| Dec 31, 2020 | 1.02B | 360.00M | 54.36% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Jiangsu Hengrui Medicine | 29.19B |
| Shenzhen Mindray Bio-Medical Electronics | 35.59B |
| WuXi AppTec | 41.48B |
| Sichuan Biokin Pharmaceutical | 5.82B |
| Zhangzhou Pientzehuang Pharmaceutical., | 10.76B |
| Aier Eye Hospital Group | 21.81B |
| Shanghai United Imaging Healthcare | 10.43B |
| Yunnan Baiyao Group Co.,Ltd | 40.10B |